Litcius/Paper detail

Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma

Xiao Huang, Qingqing Ding, Hua Guo, Yun Gong, Jun Zhao, Min Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei‐Lien Wang, Lei Huo

2020Human Pathology41 citationsDOI

Topics & Concepts

ConcordanceImmunohistochemistryCompanion diagnosticCutoffPathologyTriple-negative breast cancerBreast cancerMedicineCancerCancer researchOncologyBiologyInternal medicinePhysicsQuantum mechanicsCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCancer Cells and Metastasis
Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma | Litcius